Patients with BRAF-mutant late-stage melanoma derive a lasting overall survival (OS) benefit from treatment with the combination of dabrafenib and trametinib compared with dabrafenib and placebo, according to the final results from the COMBI-d phase III double-blinded trial.
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.
Compared with best available therapy, the novel JAK2 inhibitor pacritinib demonstrated significantly better outcomes in spleen volume reduction and symptom control when administered to patients with myelofibrosis.
Monotherapy with daratumumab demonstrated promising overall survival and objective response rates in patients with double-refractory multiple myeloma.
Patients of all ages with iodine-refractory thyroid cancer lived significantly longer when treated with the targeted agent lenvatinib, a new analysis of a randomized trial showed.
Treatment with obinutuzumab in combination with bendamustine nearly doubled progression-free survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Nivolumab (Opdivo) improved overall survival and was less toxic compared with docetaxel in chemotherapy-pretreated patients with nonsquamous non–small cell lung cancer.
Adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients who have HR-positive, HER2-negative breast cancer.
The anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with recurrent/metastatic head and neck squamous cell carcinoma.
MPDL3280A reduced the risk of death by 53% compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.
Immune checkpoint inhibition will continue to attract interest at the 2015 ASCO Annual Meeting, with a number of abstracts focused on this emerging class of agents
Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses screening for prostate cancer.
Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Enzalutamide significantly improved progression-free survival and PSA progression compared with bicalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer.
Taking the vitamin B3 pill nicotinamide could reduce the risk of recurrence for those with a history of non-melanoma skin cancer.
Adding docetaxel to standard androgen deprivation therapy significantly improved overall survival in men with newly diagnosed, hormone-naïve advanced prostate cancer.
Treatment with elotuzumab in combination lenalidomide and dexamethasone prolonged remission by 4.5 months in patients with relapsed or refractory multiple myeloma when compared with lenalidomide and dexamethasone alone.
Treatment with the PARP inhibitor olaparib demonstrated a durable ORR of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic mCRPC in a phase II multi-step adaptive trial.
Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC).
A prospective study of retrospectively analyzed blood samples of patients with nonresectable pancreatic cancer found that plasma KRAS mutational burden correlates with overall survival (OS).
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Pembrolizumab (Keytruda) achieved an overall response rate (ORR) of 45.2% among a cohort of patients with high PD-L1-expressing non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial.
Pembrolizumab (Keytruda) yielded significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase III trial of patients with advanced melanoma.
IMCgp100, an anti-CD3 antibody fragment fused to a gp100-specific T cell receptor, yielded long-lasting responses in patients with advanced melanoma.
In mid-December of 2014, the FDA approved the BRACAnalysis CDx diagnostic test to accompany the use of Lynparza (olaparib) in advanced ovarian cancer.
In a single-institution randomized prospective controlled trial of women with advanced epithelial ovarian cancer, 52.6% of patients in the PDS study arm had major complications with an MSKCC score of 3 or greater.
The angiogenesis inhibitor cediranib demonstrated acceptable activity and a tolerable safety profile as a monotherapy for patients with recurrent or persistent endometrial cancer.
Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
The addition fosbretabulin tromethamine to bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in pretreated patients with recurrent ovarian cancer enrolled in the phase II GOG186i study.